Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.4 USD | +1.04% | -4.35% | +21.84% |
05-13 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
05-08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.84% | 2.1B | |
-6.41% | 12.2B | |
-4.07% | 8.22B | |
+5.77% | 5.72B | |
+27.45% | 5.42B | |
-60.11% | 2.7B | |
+8.04% | 2.63B | |
-6.47% | 2.38B | |
-8.15% | 1.81B | |
+0.97% | 1.57B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- (MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 EPS Range $0.00 - $0.05